Medically reviewed by Doru Paul, MD Key Takeaways A JAK2 mutation can make your body produce too many blood cells.  JAK2 ...

Series B funds will enable clinical development of ATV-1601, an oral allosteric AKT1-selective inhibitor for the treatment of Hereditary ...

The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive ...

Chronic myeloid leukaemia (CML) is a paradigmatic clonal disorder primarily driven by the BCR-ABL translocation, which produces a constitutively active tyrosine kinase. Traditionally, this genetic ...

Myeloproliferative neoplasms (MPNs) represent a cluster of conditions characterized by the excessive production of blood cells within the bone marrow. Among MPN patients, abnormal quantities of red ...

The history of primary myelofibrosis dates back to 1951 and the description of four distinct clinicopathologic entities that came to be known as myeloproliferative neoplasms (MPNs): chronic myeloid ...

Manage your stage 3 ET diagnosis with this guide on high-risk treatments, side effects and new NCCN-preferred options to empower your next visit. While essential thrombocythemia (ET) is classified as ...

A panelist discusses how polycythemia vera (PV) is a rare myeloproliferative neoplasm (MPN) characterized by excessive red blood cell production, primarily affecting older adults with JAK2 mutations, ...

While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for ...

Concurrent ET and WM in a patient highlights challenges in managing coexisting myeloproliferative and lymphoplasmacytic malignancies. Distinct genetic mutations in the patient suggest independent ...